| Prev Close: | 38.27 |
|---|---|
| Open: | 38.57 |
| Bid: | 36.36 x 100 |
| Ask: | 39.66 x 100 |
| 1y Target Est: | 36.15 |
| Beta: | 1.33 |
| Next Earnings Date: | 2-May-13 |
| Day's Range: | 36.34 - 38.57 |
|---|---|
| 52wk Range: | 21.04 - 40.87 |
| Volume: | 920,060 |
| Avg Vol (3m): | 418,834 |
| Market Cap: | 1.46B |
| P/E (ttm): | 9.47 |
| EPS (ttm): | 3.84 |
| Div & Yield: | N/A (N/A) |
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Acorda Therapeutics Earnings: Here’s Why Shares are Down Nowat Wall St. Cheat Sheet(Thu 11:16AM EDT)
- Acorda Therapeutics, Inc. Earnings Call scheduled for 8:30 am ET todayCCBN(Thu 8:30AM EDT)
- Acorda Therapeutics downgraded by MKM PartnersBriefing.com(Thu 7:12AM EDT)
- Q1 2013 Acorda Therapeutics, Inc. Earnings Release - Before Market OpenCCBN(Thu 7:07AM EDT)
- InPlay: Acorda Therapeutics misses by $0.11, misses on revs; reaffirms FY13 AMPYRA sales guidanceBriefing.com(Thu 6:14AM EDT)
- Acorda Therapeutics Reports First Quarter 2013 Financial ResultsBusiness Wire(Thu 6:00AM EDT)
- ACORDA THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and EEDGAR Online(Thu 12:10AM EDT)
- Wall Street Transcript Interview with Brian Skorney, Senior Analyst at Robert W. Baird & Co.: FDA Approvals Accelerate and Opportunities Arise in Hepatitis C MarketWall Street Transcript(Mon, Apr 29)
- Zacks Bull and Bear of the Day Highlights: Overstock.com, Titan Machinery, Acorda Therapeutics, Biogen Idec and NovartisZacks(Fri, Apr 26)
- Acorda Initiates Study on rHIgM22Zacks(Thu, Apr 25)
- Acorda Therapeutics to Host Conference Call to Discuss First Quarter 2013 Financial Results on May 2, 2013Business Wire(Thu, Apr 25)
- 3 Small Biotechs Top Hedge Funds Are Investing Inat Motley Fool(Tue, Apr 23)
- Acorda Therapeutics enrolls first patient for rHIgM22 clinical trialtheflyonthewall.com(Tue, Apr 23)
- Mayo Clinic and Acorda Therapeutics Announce Initiation of Phase 1 Trial of Remyelinating Antibody in People with Multiple SclerosisBusiness Wire(Tue, Apr 23)
- Catalyst Deserves The Attentionat Seeking Alpha(Tue, Apr 23)
Press Releases
- Acorda Therapeutics Reports First Quarter 2013 Financial ResultsBusiness Wire(Thu 6:00AM EDT)
- Acorda Therapeutics to Host Conference Call to Discuss First Quarter 2013 Financial Results on May 2, 2013Business Wire(Thu, Apr 25)
- Mayo Clinic and Acorda Therapeutics Announce Initiation of Phase 1 Trial of Remyelinating Antibody in People with Multiple SclerosisBusiness Wire(Tue, Apr 23)
Reports
- ACOR: Due Diligence Review: Forensic Earnings and ValuationNew Constructs, LLC(May 2)
- ACOR - Acorda Therapeutics Inc - Rated a Hold - Research Report by ASRAlpha Street Research(Apr 29)
- ValuEngine Detailed Valuation Report for ACORValuEngine, Inc.(May 2)